GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotron Ltd (OTCPK:BITRF) » Definitions » Common Stock

BITRF (Biotron) Common Stock : $36.87 Mil (As of Dec. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Biotron Common Stock?

Biotron's quarterly common stock declined from Dec. 2023 ($38.10 Mil) to Jun. 2024 ($37.79 Mil) and declined from Jun. 2024 ($37.79 Mil) to Dec. 2024 ($36.87 Mil).

Biotron's annual common stock increased from Jun. 2022 ($37.14 Mil) to Jun. 2023 ($38.18 Mil) but then declined from Jun. 2023 ($38.18 Mil) to Jun. 2024 ($37.79 Mil).


Biotron Common Stock Historical Data

The historical data trend for Biotron's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotron Common Stock Chart

Biotron Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.47 40.40 37.14 38.18 37.79

Biotron Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.39 38.18 38.10 37.79 36.87

Biotron Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Biotron Business Description

Traded in Other Exchanges
Address
56 Delhi Road, Suite 3.3, North Ryde, Sydney, NSW, AUS, 2113
Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.

Biotron Headlines

From GuruFocus

Biotron Drug Effective Against COVID-19 In Animals

By PRNewswire PRNewswire 11-25-2021